RTP Mobile Logo
Novel and Emerging Therapeutic Strategies in the Management of Select Gastrointestinal Cancers
Released December 2019

Featuring perspectives from Dr Wells A Messersmith. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

    OVERVIEW OF ACTIVITY
    The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted therapeutics possessing unique mechanisms of action and safety profiles have led to improved outcomes in a myriad of large and rigorous clinical trials. Although this dynamic appears to be prevalent in many corners of oncology, recent advancements in the management of several prominent GI cancers have made it particularly pronounced in this area.

    The successes yielded by this rational approach to the design and evaluation of new therapies have provided medical oncologists and patients with many beneficial treatments, but the availability of this growing list of novel options may also pose a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. To bridge the gap between research and patient care, this video presentation by Wells A Messersmith uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists and other healthcare providers involved in the treatment of GI cancers with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Review recent therapeutic advances and related FDA authorizations for patients with newly diagnosed and relapsed or recurrent colorectal, gastric, hepatocellular and pancreatic cancer, and integrate this information, as appropriate, into routine clinical practice.
    • Recognize the importance of biomarker analysis for patients diagnosed with colorectal cancer (CRC) or gastric/gastroesophageal junction (GEJ)/esophageal cancer, and use this information to counsel these individuals regarding evidence-based systemic treatment options.
    • Describe the clinical indications, benefits and toxicities associated with existing and recently approved systemic therapies for metastatic CRC.
    • Use PD-L1 combined positive score, clinical factors and patient preferences to optimize systemic therapy for locally advanced or metastatic gastric/GEJ/esophageal cancer.
    • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic cancer.
    • Communicate the benefits and risks of approved and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular carcinoma.
    • Recall available and emerging data with other investigational agents currently in clinical testing for GI cancers, and where applicable, refer eligible patients for trial participation or other expanded access programs.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GrandRoundsGI19/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Presenting Faculty Member

    Wells A Messersmith, MD
    Professor and Head, Division of Medical Oncology
    Associate Director for Translational Research
    University of Colorado Cancer Center
    Aurora, Colorado

    Contract Research: ALX Oncology, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Exelixis Inc, Immunomedics Inc, Incyte Corporation, OncoMed Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc.

    Project Steering Committee Members

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
    Vice-Chair and Section Lead, Division of Medical Oncology
    Medical Director, Cancer Clinical Research Office
    Senior Associate Consultant
    Mayo Clinic
    Phoenix, Arizona

    Advisory Committee: Amgen Inc, Immuneering Corporation, Imugene; Consulting Agreements: AbbVie Inc, Array BioPharma Inc, Bayer HealthCare Pharmaceuticals; Contracted Research: Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Genentech, Ipsen Biopharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, SillaJen.

    Johanna Bendell, MD
    Chief Development Officer
    Director, Drug Development Unit Nashville
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Rgenix, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Shattuck Labs, Sierra Oncology, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad; Data and Safety Monitoring Board: Five Prime Therapeutics Inc.

    Howard S Hochster, MD
    Distinguished Professor of Medicine
    Rutgers Robert Wood Johnson Medical School
    Rutgers-CINJ Associate Director, Clinical Research
    Director, Clinical Oncology Research, RWJBarnabas Health
    New Brunswick, New Jersey

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceuticals Group Co Ltd, Exelixis Inc, Roche Laboratories Inc.

    John L Marshall, MD
    Chief, Hematology and Oncology
    Director, Ruesch Center for the Cure of GI Cancers
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Advisory Committee, Consulting Agreements and Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Indivumed GmbH, Roche Laboratories Inc, Taiho Oncology Inc; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Merck, Roche Laboratories Inc, Taiho Oncology Inc.

    Eileen M O’Reilly, MD
    Winthrop Rockefeller Chair in Medical Oncology
    Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
    Gastrointestinal Oncology Service
    Associate Director
    David M Rubenstein Center for Pancreatic Cancer
    Attending Physician, Member
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Pfizer Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, Incyte Corporation, Lilly, Novartis.

    Philip A Philip, MD, PhD
    Kathryn Cramer Endowed Chair in Cancer Research
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Vice President of Medical Affairs
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    Advisory Committee: ASLAN Pharmaceuticals, BioLineRx, Caris Life Sciences, Celgene Corporation, Eisai Inc, Erytech Pharma, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Merck, TriSalus Life Sciences; Consulting Agreements: AbbVie Inc, Merck, Rafael Pharmaceuticals Inc, TriSalus Life Sciences; Contracted Research: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, BioLineRx, Boston Biomedical Inc, Bristol-Myers Squibb Company, Caris Life Sciences, Celgene Corporation, Halozyme Inc, Incyte Corporation, Lilly, Novartis, Novocure, QED Therapeutics, Rafael Pharmaceuticals Inc, Roche Laboratories Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: ASLAN Pharmaceuticals, Blueprint Medicines, Erytech Pharma, Lexicon Pharmaceuticals Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Merck.

    Alan P Venook, MD
    The Madden Family Distinguished Professor of
    Medical Oncology and Translational Research
    Shorenstein Associate Director, Program Development
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Array BioPharma Inc, Bristol-Myers Squibb Company, Eisai Inc, Genentech, Roche Laboratories Inc, Taiho Oncology Inc; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Genentech, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, Halozyme Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Eisai Inc, Lilly and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2019
    Expiration date: December 2020

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):